Study links age, insurance, but not race, to chemo rates

August 10, 2012
Study links age, insurance, but not race, to chemo rates
For women with breast cancer, disease characteristics correlate significantly with chemotherapy receipt, with no indication of racial barriers to treatment, according to a study published online Aug. 6 in the Journal of Clinical Oncology.

(HealthDay) -- For women with breast cancer, disease characteristics correlate significantly with chemotherapy receipt, with no indication of racial barriers to treatment, according to a study published online Aug. 6 in the Journal of Clinical Oncology.

To examine disparities in receipt of adjuvant chemotherapy, Jennifer J. Griggs, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues recruited women diagnosed with and identified through the Detroit, Michigan, or Los Angeles County Surveillance, Epidemiology, and End Results registry to complete a survey.

The researchers found that, for the 1,403 women included in the analytic sample, disease characteristics correlated significantly with receipt of chemotherapy in multivariable models. Low-acculturated Hispanics and high-acculturated Hispanics were more likely to receive chemotherapy than non-Hispanic whites (odds ratio [OR], 2.00 and 1.43, respectively). Black women were less likely than non-Hispanic whites to receive chemotherapy, but the difference was not significant (OR, 0.83; 95 percent confidence interval, 0.64 to 1.08). Even in women younger than 50 years of age, increasing age correlated with lower rates of chemotherapy receipt, as did Medicaid insurance.

"In conclusion, it seems that race and ethnicity need not pose barriers to receipt of ," the authors write. "Such a finding is encouraging as we continue to address racial and in the receipt of quality cancer care. Nonetheless, differences and disparities do exist in receipt of chemotherapy according to age, insurance, and employment status."

Explore further: Gene expression profile testing increasing in breast cancer

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Gene expression profile testing increasing in breast cancer

May 18, 2012
(HealthDay) -- From 2006 to 2008, the use of gene expression profile (GEP) testing increased, correlating with a decrease in the percentage of women with hormone receptor (HR)-positive breast cancer receiving adjuvant chemotherapy, ...

Even with insurance, racial disparities in breast cancer treatment persist

July 27, 2012
More White women are diagnosed with breast cancer than Black women, yet Black women with breast cancer have a higher mortality rate. One potential explanation for this disparity is delayed treatment, perhaps due to differences ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.